Vagus Nerve Stimulation (VNS) — NCD 230 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 230 governing Vagus Nerve Stimulation coverage, with an effective date of February 7, 2026. Here's what billing teams need to know now.

CMS Vagus Nerve Stimulation coverage policy under NCD 230 Medicare covers two distinct indications with very different rules — and the criteria for treatment resistant depression (TRD) are complex enough to cause real claim exposure if your team isn't billing them correctly. This policy governs VNS as a durable medical equipment benefit as well as incident-to and physicians' services billing. No specific CPT or HCPCS codes are listed in the updated NCD 230 policy document, so your team needs to verify current procedure codes with your Medicare Administrative Contractor before submitting claims.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Vagus Nerve Stimulation (VNS) — NCD 230
Policy Code	NCD 230
Change Type	Modified
Effective Date	2026-02-07
Impact Level	High
Specialties Affected	Neurology, Psychiatry, Neurosurgery, DME Suppliers
Key Action	Audit all VNS claims against the updated TRD patient criteria and CED study requirements before billing

---

CMS Vagus Nerve Stimulation Coverage Criteria and Medical Necessity Requirements 2026

CMS covers VNS under two separate pathways. Each has its own medical necessity criteria. Mixing them up is an easy way to generate a claim denial.

Pathway 1: Refractory Epilepsy

VNS for epilepsy has been covered since July 1, 1999. The criteria are straightforward. The patient must have medically refractory partial onset seizures, and surgery must be either contraindicated or previously attempted and failed.

This is the cleaner billing pathway. Medical necessity documentation should confirm the seizure type, the failure of antiepileptic medications, and the surgical evaluation outcome. If surgery was never evaluated, your documentation needs to explain why it's not recommended — not just that the patient declined.

Pathway 2: Treatment Resistant Depression (TRD)

Coverage for TRD has been in place since February 15, 2019, but it's not standard coverage. CMS covers FDA-approved VNS devices for TRD only through Coverage with Evidence Development (CED). That means your patient must be enrolled in a CMS-approved, double-blind, randomized, placebo-controlled trial.

This is not a minor administrative requirement. CED coverage means the claim is tied to an active research protocol. If the study your patient is enrolled in isn't CMS-approved, the claim isn't covered. Full stop.

The CMS Vagus Nerve Stimulation coverage policy also allows for a prospective longitudinal study extension — but only after the randomized controlled trial completes enrollment and shows positive interim findings. That extension pathway doesn't open up billing eligibility for patients outside the original protocol.

Patient Criteria for TRD — Read These Carefully

CMS defines TRD with specific, measurable criteria. Your documentation must support all of them.

The patient must currently be in a major depressive disorder (MDD) episode lasting at least two years, or have had at least four MDD episodes including the current one. Diagnosis must use the most current DSM edition with a structured clinical assessment — not just a clinical note that says "MDD."

The patient's depressive illness must also show a minimum of four prior failed treatments at adequate dose and duration. "Adequate" here means measured by a validated tool designed for that purpose — not physician judgment alone.

The policy defines response and remission in specific quantitative terms. Response means at least a 50% improvement in depressive symptoms from baseline, measured by a guideline-recommended depression scale. Remission means scoring below the threshold on that same type of scale. Your documentation needs to reflect these definitions, not informal clinical descriptions.

Prior authorization requirements for VNS under the TRD CED pathway effectively exist through the study approval mechanism — your patient's enrollment in the CMS-approved trial is the authorization. If you're billing outside that structure, you're billing outside coverage.

---

CMS Vagus Nerve Stimulation Exclusions and Non-Covered Indications

CMS does not cover VNS for TRD outside of a CMS-approved clinical trial. This is the clearest and most financially significant exclusion in NCD 230.

A patient who has TRD but is not enrolled in an approved study is not a covered VNS patient under this policy — regardless of the severity of their condition, the number of prior treatment failures, or the physician's clinical judgment. The coverage policy is explicit on this point.

The policy also limits the TRD CED extension to prospective longitudinal studies that were described in the original trial protocol. That's a technical requirement that affects which studies qualify. If the longitudinal component wasn't built into the original protocol, it doesn't qualify for the extension pathway.

The research questions embedded in the protocol requirements are extensive — nine separate research questions covering response rates, remission rates, time to response, time to remission, distribution of response and remission months, patient variables associated with success, observed harms, and changes in disability, quality of life, psychiatric status, and suicidality. These aren't billing questions. But if the study your facility participates in doesn't address all of them, the study itself may not be CMS-approved — which means your TRD claims aren't covered.

---

Coverage Indications at a Glance

---

CMS Vagus Nerve Stimulation Billing Guidelines and Action Items 2026

Vagus nerve stimulation billing under NCD 230 is not a set-it-and-forget-it process. The TRD pathway especially requires active coordination between your clinical, research, and billing teams. Here are the steps your team should take now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Vagus Nerve Stimulation Under NCD 230

A Note on Code Coverage for NCD 230

The updated NCD 230 policy document does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for NCDs, which set coverage rules at a national level while leaving code-level specifics to Medicare Administrative Contractors and local coverage determinations.

For vagus nerve stimulation billing, your MAC is the definitive source. Contact your MAC or check their LCD and billing guidelines database for the applicable procedure codes for VNS implantation, lead placement, device programming, and follow-up services.

What to Ask Your MAC

When you contact your MAC, ask specifically about:

• The HCPCS or CPT codes for VNS pulse generator implantation
• Codes for VNS lead placement and revision
• Device programming visit codes
• Applicable ICD-10-CM codes for refractory partial onset seizures and for MDD/TRD diagnoses that support medical necessity
• Whether any local coverage determination modifies or restricts NCD 230 in your jurisdiction

Do not submit claims using codes you're not sure about. A single miscoded VNS claim can trigger a broader audit, especially given the high device cost and the complexity of the TRD CED pathway.

---